Abstract: Mechanisms occurring in the thymus and periphery are responsible for the generation and maintenance of tolerance in the immune system. Various reports have shown that the existence of an antigen in the peripheral circulation results in tolerance induction towards that protein. These observations imply that the lack of a self antigen can lead to induction of autoimmunity. Previously we have reported that Tyrosinase related protein-2 (TRP-2) transcripts from peripheral blood mononuclear cells (PBMCs) are absent in vitiligo patients but present in healthy individuals. Here, we show that MART1 (Melanoma antigen recognized by T cells) transcripts are not detected in the PBMCs of vitiligo patients but is detected in healthy controls. Our result suggests that as MART1 is not expressed in the PBMCs, MART1 is also not available for induction and maintenance of peripheral tolerance in vitiligo patients. We therefore conclude that nonexpression of MART1 in PBMCs of vitiligo patients may be somehow responsible for the tolerance breakdown finally resulting in the induction of autoimmunity seen against these self antigens in vitiligo.
Introduction
Self tolerance is defined as the state of not reacting destructively to self antigens (self-Ag) expressed on cells, tissues or organs. Mechanisms that occur in the thymus (central tolerance) and secondary lymphoid tissues (peripheral tolerance) are responsible for induction and maintenance of self tolerance. Central tolerance generation involves the deletion of maturing T cells that have a strong affinity towards self-Ag plus Major Histocompatibility Complex (MHC) or MHC alone (negative selection). Mature but naïve T cells that pass the central tolerance process, enter the peripheral circulation and are capable of activating the immune system upon recognition of an antigen along with proper costimulatory signals. T cells may also be made tolerant to self antigens found in the periphery by various mechanisms and thereby maintain a non destructive state, called peripheral tolerance.
Various mechanisms -clonal deletion, anergy, ignorance and role of regulatory T (T reg) cells -give rise to peripheral tolerance [1] [2] [3] [4] [5] [6] . Lack or loss of selftolerance can lead to the induction of autoimmune responses, cellular and tissue damage, and eventually the onset of autoimmune disease. The presence or absence of a self antigen is one of the several factors that modulate the immune system and thereby contribute to the breakdown of tolerance. Thus, it appears important that any self antigen should be constitutively present in the system so that it is exposed to the T cells throughout life. This statement is unswervingly supported by a range of observations showing that antigen persistence allows T cells to be tolerant to that antigen. For example, den Boer et al. [7] demonstrated the role of the antigen in inducing peripheral tolerance by vaccinating mice with cytotoxic T lymphocyte (CTL) epitope derived from human adenovirus type 5 E1A. Raimondi et al. [8] also showed that peripheral tolerance to Bpep peptide and its specific T cell receptor (TCR) is observed when antigen presentation is unceasing, while transient presentation leads to activation of T cells. Therefore, they suggested that the persistence of antigen presentation is one of the main pathways to peripheral tolerance. In the light of the above observations, we have reported the absence of TRP-2 in the PBMCs of generalized vitiligo patients, which is present in healthy individuals [9] , and we have suggested that the absence of TRP-2 is likely to contribute to immune response manipulation leading to vitiligo manifestation.
Of the various autoimmune diseases, vitiligo is one of the least understood diseases. It is a depigmentation disorder of the skin. Several hypotheses have been put forward to explain the pathogenesis of vitiligo [10, 11] of which the autoimmune hypothesis is the most popular one [12] . Alternative hypotheses include other aetiological factors, such as cellular defects and genetic factors, playing a role in the depigmentation process [13] . Although there is strong evidence [14] [15] [16] supporting the direct or indirect contribution of the immune system in vitiligo, it is still not apparent as to how these immune responses are initiated against a range of vitiligo specific autoantigens such as TRP-2, MART1 etc. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Thus we tested the hypothesis that native expression or lack of expression of the autoantigen gene(s) in the peripheral circulation is a contributing factor in the initiation of the disease. In the present article we report that the transcript of MART1 (Melanoma antigen recognized by T cells) is absent in the PBMCs of vitiligo patients but is detected at low levels in healthy individuals. Therefore, we conclude that MART1, similar to TRP-2 [9] , is likely to be unavailable in the peripheral circulation through native expression in PBMCs of vitiligo patients. Thus, we further conclude that absence of vitiligo specific autoantigens is possibly the initiating factor in the peripheral tolerance breakdown in vitiligo patients, resulting in the initiation of the disease.
Experimental Procedures

Patients
We analyzed peripheral blood samples from 42 individuals actively suffering from vitiligo (13 females and 29 males) and 22 healthy donors (6 females and 16 males) (age range, 7-60 years). All patients were diagnosed as having generalized type of vitiligo by medical practitioner. No patient had any other associated autoimmune disease except for patient number 13 (as provided in Table 1 ), who had Rheumatoid arthritis also. Samples were collected only after informing the patients/individuals about the purpose of the study and the necessary approvals and written consents had been obtained.
Sample collection and separation of adherent and non-adherent cells
An aliquot (10 ml) of peripheral blood was collected in EDTA coated vials (HIMEDIA, Mumbai, India 
RNA isolation and reverse transcriptase (RT) PCR with primers specific for MART1
Total RNA was isolated from monocytes and non-adherent cells obtained from human subjects as well as SK-MEL-28 cell line using total RNA extraction kit (Bangalore Genei, Bangalore, India). The quality of the RNA samples was assessed by inspecting the 28S and 18S bands following agarose gel electrophoresis. Two μg of each of all the RNA samples were used with Oligo(dT 18 ) for cDNA synthesis in a 20 μl system using M-MuLV RT PCR kit (Bangalore Genei, India) following the manufacturers' instructions. Briefly, the RNA and Oligo(dT18) mixture was incubated at 65ºC for 10 min, centrifuged briefly and kept at room temperature for 2 min. Into this, was added RNAsin, DTT, RT buffer, dNTP and Reverse transcriptase, as instructed by the manufacturer and incubated further at 37ºC for 1 h, followed by 5 min incubation at 95ºC. All the cDNA preparations were then amplified for 30 cycles in a thermal cycler (Eppendorf, Germany) with β-actin specific primers (BetaF 5'-AGCGGGAAATCGT GCGTGACA, BetaR 5'-CGCAACTAAGTCATAGTCCG, generating an amplicon of 536 bp) by taking 2 μl of the cDNA in a 25 μl system. This was used as control for synthesis of cDNA. Amplification conditions were as follows: initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 45 s, annealing at 66°C for 30 s, extension at 72°C for 1 min and a final extension at 72°C for 6 min. Controls for genomic DNA contamination included amplification of the total RNA without reverse transcription which did not give any amplicon (result not shown). PCR amplifications were then performed with specific primers for MART1 in a 25 μl system with 2 μl of the first strand cDNA, 0.6 μM dNTPs, 1.5 mM MgCl 2 and 1.25 pmol each of the forward and reverse primers. This was amplified for 30 cycles after the addition 0.5 U of Taq polymerase. Primers used were as follows: Mart1 F5'ATGCCAAGAGAAGATGCTC, Mart1 R5'TTAAGGTGAATGAAG TGGTG which is expected to generate an amplicon of 357 bp. Amplifications were carried out under the following conditions: an initial denaturation at 94ºC for 5 min followed by 30 cycles of denaturation at 94ºC for 45 s, annealing at 51ºC for 30 s, and extension at 72ºC for 30 s and a final extension at 72ºC for 20 min.
Cell culture
SK-MEL-28 [27] , a human melanotic melanoma cell line (National Centre for Cell Science, Pune, India), was cultured in RPMI 1640 until fully confluent. After harvesting the cells, total RNA was isolated using the RNA purification kit mentioned above. This cell line is known to express MART1. Thus it was used as a positive control for the expression of MART1 in this study.
Cloning, sequence analysis and probe preparation
For cloning, PCR products (MART1 and β-actin) were purified from low melting point agarose followed by extraction with phenol: chloroform. The purified products were ligated into T vector (InsTAclone PCR cloning kit, Fermentas Life Sciences, EU) and used for transformation. Clones giving appropriate insert size as confirmed by PCR followed by RE digestion, were sequenced by automated ABI 3100 Genetic Analyzer at Bangalore Genei, Bangalore, India. After confirming the identity of the amplicon, plasmid from these clones was used for amplifying the MART1 and β-actin specific DNA. The amplicons thus obtained were used for probe preparation following elution from agarose gels. 100 μg of the eluted amplicons were used for probe generation following manufacturers' instructions (Amersham Gene Images Alkphos Direct Labelling and Detection System, GE Healthcare, UK).
RT PCR and Southern hybridization
For RT PCR and Southern hybridization, 13 patient and 11 control samples were included. Details of the patients are provided in Table 1 . From the RNA samples (with the concentration normalized) cDNA was synthesized. After confirming the synthesis of first strand cDNA, amplification for 30 cycles was performed with MART1 specific primers, as mentioned earlier, for all the samples from patients, controls and SK-MEL-28 used for this experiment. The cDNA prepared from SK-MEL-28 RNA was used as the positive control in all the experiments. For transfer onto nylon membrane, 15 μl of the amplified product was used for fractionation in 0.8% agarose gel. Only 1 μl of the 20x diluted preparation of MART1 specific amplicon from SK-MEL-28 and β-actin was used for transfer for all samples. After capillary transfer onto a positively charged nylon membrane (Hybond, Amersham, GE Healthcare, UK), membranes were exposed to UV for cross-linking. All the steps from here onward were as instructed by the manufacturer of the kit used (Amersham Gene Images Alkphos Direct Labelling and Detection System, GE Healthcare, UK). Hybridizations were carried out overnight at 55ºC in a hybridization oven. This was followed by washing twice with primary wash buffer (2 M urea, 0.1% w/v SDS, 50 mM di-sodium hydrogen phosphate pH7.0, 150 mM NaCl, 1 mM MgCl 2 , 0.2% w/v blocking reagent) for 10 min at 55ºC with constant gentle shaking. The membranes were then further washed twice for 5 min each at room temperature with secondary wash buffer containing 50 mM Tris base, 100 mM NaCl and 2 mM MgCl 2 . Following this, the membranes were flooded for 2-5 min with CDPstar for chemifluorescent detection. The membranes were then exposed to X-ray films (longest exposure time was 8 h for probing with MART1 specific probes in case of both monocytes and non-adherent PBMCs from patients and controls). Following the same protocol, β-actin was always used as the internal control for the working of the RT PCR and Southern hybridization.
Results
Quality of RNA and cDNA used
The quality of the RNA samples from monocytes and non-adherent WBCs from both patients and controls as well as SK-MEL-28 cells used in the study was first confirmed by agarose gel electrophoresis. Following confirmation of clear 28S and 18S rRNA bands, samples were then used for cDNA synthesis. Every cDNA preparation used was first checked by carrying out a PCR reaction with β-actin specific primers. Using β-actin primers, all the samples analyzed gave a single band of 536 bp amplicon (data not provided). To rule out genomic DNA contamination, PCR amplification was performed without prior reverse transcription of the RNA samples. Further experimentation was carried out if this did not yield any amplicon, confirming the quality of the RNA preparation.
Detection of MART1 specific transcripts by RT PCR
PCR with specific primers for MART1 was carried out with cDNA prepared from monocytes and non-adherent WBCs from both patients (42) and controls (22) as well as SK-MEL-28 (melanocyte) cells. Using the specific primers, amplicon of expected size (357 bp) was seen after PCR amplification of cDNA from SK-MEL-28 cells only. No visible amplicon of MART1 specific transcript was obtained after PCR amplification in any of the samples either from patient or control subjects even after loading the entire amplified sample (data not provided).
Sequence analysis to confirm the identity of the amplicons
β-actin and MART1 amplicons obtained from SK-MEL-28 cDNA were cloned and their sequence identities confirmed. Sequence result confirmed the identity of the transcripts. Amplicons were used for probe preparation only after confirmation of their sequence.
Southern hybridization of RT PCR products
Since MART1 transcript was not seen in any of the patient or control samples after RT PCR, a different approach of RT PCR followed by Southern hybridization was attempted. Briefly, cDNA from patients, controls and SK-MEL-28 was amplified with MART1 specific primers and used for transfer onto nylon membrane after fractionation in 0.8% agarose gel. This was followed by probing with a MART1 specific DNA probe. Even after 8 h of exposure, MART1 transcripts could not be detected either in monocytes (Figure 1d ) or non-adherent WBC samples from vitiligo patients (except for sample 1 and 3 in case of non-adherent WBCs) (Figure 2d ) while corresponding preparations derived from the same samples gave strong signals at 10 min exposure following hybridization with β-actin specific probe (Figure 1c and 2c) . SK-MEL-28 cell line was used as the positive control and both MART1 and β-actin signal from it was very strong even at 10 min exposure. Probing for MART1 in control subjects monocytes also gave a signal, although the signal was very weak in samples 2 and 8 compared to rest of the control subjects ( Figure 1b) . Moreover, the signal from control subjects was always weak (even after 8 h) as compared to that from SK-MEL-28 cells (10 min). Also, the MART1 signal from all the control non-adherent WBC samples was very weak and showed variance (Figure 2b ) although the monocyte samples from the same individuals were positive for this transcript as mentioned earlier (Figure 1b) . Samples 1 and 3 showed very faint bands after longer exposure time (8 h) (Figure 2d ) and the rest of the samples (samples 2, 4, and 5) did not produce any signal. Furthermore, monocyte samples (samples 1 through 11) from patients did not produce any signal, either. β-actin probe was used for every experiment and it produced clear signals in all the samples including SK-MEL-28 ( Figures 1a, 1c, 2a and 2c) indicating there was no problem at RNA, cDNA or hybridization level. Probing for β-actin in all controls, samples and SK-MEL-28 gave strong signals even at very low exposure time (10 min). Furthermore, some weak bands (Figures 1b, 2b and 2d ) of size below that expected for MART1 amplified product could be seen in all the controls and all the non-adherent WBCs from patients. At this moment we cannot comment much on this observation. Nevertheless, it is possible that those are signals arising from probing to dimers of primers specific for MART1 as was apparent in the in the ethidium bromide stained gels (data not shown).
Discussion
This report further confirms the hypothesis that the absence of transcript of autoantigen may be the cause for vitiligo manifestation. Previously, we have reported the absence of TRP-2, an autoantigen considered to have a role in vitiligo pathogenesis [9] . Now we report the transcript profile of another autoantigen, MART1, suggested by others to be involved in the pathogenesis of vitiligo. We found that transcript of MART1 is absent from the PBMCs of most of the vitiligo patients. Specifically, of the non-adherent WBCs sampled, 3 of 5 patients were negative for MART1 and all of 13 monocytes samples
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. Southern blot of RT (Reverse transcriptase) PCR amplicons derived from monocytes and using various probes. cDNA from control (eleven samples) and patient (thirteen samples) monocytes was amplified with primers specific for β-actin and MART1 in separate reactions. The whole amplified product in case of MART1 from both monocytes and non-adherent WBCs from patients and controls, and only 1 µl of 20x diluted in case of β-actin and MART from SK-MEL-28 cells, were fractionated in 0.8% agarose gel and transferred onto nylon membranes. This was followed by hybridization with DNA probe specific for MART1. The same membranes were reprobed with DNA probe specific for β-actin after deprobing the previous probe. were negative. However, it is found to be present in healthy individuals (Figure 1b and Figure 2b ). Even though we did not analyze at the protein level, based on the non detection of the transcripts, we presume that MART1 is also not available in the peripheral circulation of these vitiligo patients. Several workers [28] [29] [30] [31] [32] [33] [34] [35] have shown that native or ectopically expressed antigen, and therefore its presence in the periphery, directly correlates with the tolerization to that antigen. In other words, persistent and systemic expression and presence of an antigen results in tolerization to that antigen in the periphery. In this context, observations made by den Boer et al. [7] , Raimondi et al. [8] and others [28] [29] [30] [31] [32] [33] [34] [35] confirm that antigen persistence is an utmost necessity for maintaining a steady state tolerance in the periphery. From these observations it is apparent that absence of in vivo expression, and thereby the non-representation of any antigen, will lead to failure to recognize a self-antigen in the periphery resulting in the activation of T cells when the antigen is encountered. In the light of the above observations, we have already reported that TRP-2 is absent in vitiligo PBMCs [9] . Thus, taken together, our previous and the present observations indicate an obvious relationship between absence of vitiligo autoantigens in the periphery and the initiation of the disease seen in vitiligo patients. In this context, it is plausible that the absence of TRP-2 and MART1 contributes directly to the breakdown of peripheral tolerance towards these antigens in vitiligo patients.
Above all, the present study also reports, the presence or absence of MART1 transcripts in the adherent WBCs representing a compartment of peripheral antigen presenting cells (APCs). Native expression of self antigens by peripheral antigen presenting cells was recently demonstrated by Garcia et al. [36] , Pugliese et al. [37] and Narendran et al. [38] . In separate studies, the authors have shown that insulin, GAD65 and ICA2 are expressed in the monocytes [36] and PBMCs of the myeloid lineage [38] in humans. It was also shown that, peptides generated from insulin and GAD65 were present on the surface of these APCs [36] . It is important to note that the above mentioned proteins are autoantigens against which immune reactions are seen in type I diabetes patients. Based on these results, the authors suggested that native expression of autoantigens by APCs might have a critical role in modulating the immune system.
The relevance of our observations with the ones mentioned above, in the context of MART1 expression is that, its transcript is also present in the APCs in the periphery. We could detect transcripts of MART1 in both monocytes and the non-adherent PBMCs (comprising B cells) from all the 11 healthy individuals included for Southern hybridization analysis and few patients (2 of 5). Both monocytes and B cells are also professional antigen presenting cells [39] . However, as we did not separate B cells from rest of the non-adherent WBCs in the present study and also due to lack of reports on the native expression of self antigens by B cells we cannot say for sure that expression seen in healthy individuals is from B cells. Separately analyzing B cells will shed the light on whether the transcript seen is from B cells.
Moreover, we have observed a variation in the presence of MART1 transcripts within patients (faintly detected in non-adherent WBC samples from patients 1 and 3, Figure 2d ). This would mean that in patients with no detectable transcript of MART1, hence absence of the protein, the autoimmune response is probably against this protein also. This statement is in agreement with reports by others that not all the vitiligo patients have the same autoantigens as targets of the autoimmune response. Autoantibodies to different autoantigens are seen in different individuals (reviewed by Ongenae et al., 2003, [13] ).
Hence, we conclude that absence of expression of MART1 in vitiligo patients has a direct connection in the breakdown of peripheral tolerance. The observed variation in the presence of MART1 transcripts between patients is in agreement with the reports by others showing that autoimmunity seen in different individuals is directed against different proteins. Nonetheless, at this juncture we do not know the cause for the deficiency of MART1 transcripts from the monocytes and the B cell containing non-adherent WBCs from the vitiligo patients. Whatever the reason is for the partiality in the transcription pattern of this gene between healthy individuals and these vitiligo patients, dissecting the molecular mechanisms implicated would help in strategies and approaches for treating the depigmentation process.
